1Menges M,Hoehler T. Current strategies in systemic treatment of gas- tric cancer and cancer of the gastroesophageal junction[J].Cancer Res Clin Oncol,2009,135 (1) :29.
2Sehgal SN, Sirolimus. Its discovery, biological properties, and mecha- nism of action[J]. Ransplant Proc ,2003,35 ( 3 ) :7S.
3De Vita F, Giuliani F, Silvestris N, et al. Human epidermal growth factor receptor2 ( HER2 ) in gastric cancer : a new therapeutic target[J]. Cancer Treat Rev ,2010,36 ( suppl 3 ) : sl 1.
4Matsui Y , Inomata M, Tojigamori M, et al. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti- HER2 anibody in a murine model[J]. International Journal of Oncol- ogy,2005,27(3) : 681.
5Marx Ah,Tharun L, Muth J, et al. HER-2 amplification is highly ho- mogenous in gastric cancer[J]. Hum Pathol,2009,40 ( 6 ) :769.
6Nissim H, Nahum S. Up stream and downstream of mTOR[J]. Genes, 2004,18 (16) :1926.
7Guanzhen Yu, Jiejun Wang, Ying Chen, et al. Overexpression of phos- phorylated mammalian target of rapamycin predicts lymph node metas- tasis and prognosis of chinese patients with gastric cancer[J]. ClinCancer Res,2009,15 ( 1 ) : 1821.
8An JY, Kim KM, Choi MG,et al. mTOR expression in gastric cancer tissues and in metastatic lymph nodes and its association with clinical outcome[J]. International Journal of Cancer,2010,126 ( 12 ) : 2904.
9Gomez Ronero J. New concepts in phospholipase D signaling in in- flammation and cancer[J]. Scient World ,2010, 10 (5) : 1356.
2Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett, 2005, 10:479-498
3Sarbassov D D, Guertin D A, Ali S M, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307: 1098-1101
4Lu R, Wang X, Chen Z F, et al. Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells. J Biol Chem, 2007, 282:12249-12259
5O'Reilly K E, Rojo F, She Q B, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res, 2006, 66:1500-1508
6Vivanco I, Sawyers C L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer, 2002, 2:489-501
7Bjornsti M A, Houghton P J. The TOR pathway: a target for cancer therapy. Nat Rev, Cancer, 2004, 4:335-348
8Thomas G.The S6 kinase signaling pathway in the control of development and growth. Biol Res, 2002, 35:305-313
9Huang S, Houghton P J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opinion Invest Drugs, 2002, 3:295 -304
10Fang J Y, Xiao S D. Alteration of DNA methylation in gastrointestinal carcinogenesis. J Gastroenterol Hepatol, 2001, 16:960-968
